Document is current
Any future updates will be listed below
-
Authors
Khadka, Sunada
Arthur, Kenisha
Barekatain, Yasaman
Behr, Eliot
Washington, Mykia
Ackroyd, Jeffrey
Crowley, Kaitlyn
Suriyamongkol, Pornpa
Lin, Yu-Hsi
Pham, Cong-Dat
Zielinski, Rafal
Trujillo, Marissa
Galligan, James
Georgiou, Dimitra K.
Asara, John
Muller, Florian https://orcid.org/0000-0001-7568-2948
-
Funding
Funding for this research was provided by:
National Institutes of Health (R21CA226301, CDP SPORE P50CA127001-07, SPORE 2P50CA127001-11A1)
American Cancer Society (RSG-15-145-01-CDD)
National Comprehensive Cancer Network (YIA170032)
Elsa U. Pardee Foundation (NA)
Uncle Kory Foundation (NA)
The Larry Deaven Fellowship (NA)
CPRIT (RP170067)
- License Information
-
More Information
Article History
Received: 7 December 2020
Accepted: 18 April 2021
First Online: 25 June 2021
Declarations
:
: All animal (mice) involving experiments were approved by MD Andersons’s Institutional Animal Care and Use Committee (IACUC).
: All authors give consent for publication of the manuscript.
: The authors declare no competing financial interests. F.L.M. is an inventor on a patent covering the concept of targeting ENO1-deleted tumors with inhibitors of ENO2 (US patent 9,452,182 B2) and an inventor on a patent application describing the synthesis and utility of novel pro-drug inhibitors of enolase US 62/797,315 (filed Jan. 27, 2019). F.L.M. and Y-H.L. are inventors on a patent application for the use of enolase inhibitors for the treatment of ENO1-deleted tumors (US patent 10,363,261 B2).
